This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Sanofi, Sanofi-Aventis. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Lucie Manache-Alberici: Innovator in Antibody-Drug Conjugate Formulations
Introduction
Lucie Manache-Alberici is a prominent inventor based in Paris, France. She has made significant contributions to the field of medicine, particularly in the development of innovative treatments for multiple myeloma. With a total of 2 patents to her name, her work is paving the way for advancements in cancer therapy.
Latest Patents
One of her latest patents is focused on a CEACAM5 antibody-drug conjugate formulation. This patent outlines methods for treating multiple myeloma, including refractory and relapsed cases. The disclosure provides a comprehensive approach that involves administering an anti-CD38 antibody, pomalidomide, and dexamethasone to individuals who have undergone at least two prior therapies for multiple myeloma. Additionally, the methods aim to improve renal impairment in patients suffering from this condition.
Career Highlights
Throughout her career, Lucie has worked with notable companies such as Sanofi and Sanofi-Aventis. Her experience in these organizations has allowed her to collaborate with leading experts in the pharmaceutical industry, enhancing her knowledge and expertise in drug development.
Collaborations
Lucie has collaborated with talented individuals, including Audrey Bonestebe and Sylvain Huille. These partnerships have contributed to her innovative research and the successful development of her patents.
Conclusion
Lucie Manache-Alberici is a trailblazer in the field of antibody-drug conjugates, with her work significantly impacting the treatment of multiple myeloma. Her innovative approaches and collaborations continue to inspire advancements in cancer therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

